Hiroyuki Muraoka

发表

Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics

T. Onitsuka, K. Ohi, N. Yasui-Furukori, 2022, Frontiers in Psychiatry.

The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project.

K. Kasai, T. Kishimoto, Tadasu Horai, 2022, Asian journal of psychiatry.

Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study.

T. Onitsuka, K. Ohi, N. Yasui-Furukori, 2022, Asian journal of psychiatry.

Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study

T. Onitsuka, T. Kishimoto, K. Ohi, 2022, The international journal of neuropsychopharmacology.

Unmet needs of patients with major depressive disorder – Findings from the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study

T. Onitsuka, T. Kishimoto, Tadasu Horai, 2020, Psychiatry and clinical neurosciences.

The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the “Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)” project

T. Onitsuka, T. Kishimoto, K. Ohi, 2022, Annals of General Psychiatry.

Association between the examination rate of treatment‐resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study

T. Onitsuka, K. Miura, K. Ohi, 2021, Neuropsychopharmacology reports.

Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study

T. Onitsuka, T. Kishimoto, K. Miura, 2020, Neuropsychopharmacology reports.

Escitalopram attenuates fear stress‐induced increase in amygdalar dopamine following methamphetamine‐induced sensitisation: Implications of fine‐tuning action of selective serotonin reuptake inhibitors on emotional processing

K. Nishimura, J. Ishigooka, M. Yamada, 2018, European journal of pharmacology.

Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study

T. Onitsuka, T. Kishimoto, K. Ohi, 2019, Psychiatry and clinical neurosciences.

Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders

T. Onitsuka, T. Kishimoto, Tadasu Horai, 2022, Neuropsychopharmacology reports.

Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia”

T. Onitsuka, T. Kishimoto, K. Ohi, 2022, Neuropsychopharmacology reports.

Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score‐matched analysis

Y. Hirano, Tadasu Horai, K. Ohi, 2022, Psychiatry and clinical neurosciences.

Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia.

T. Onitsuka, K. Ohi, Y. Takaesu, 2022, Journal of clinical psychopharmacology.

Dopamine dynamics during emotional cognitive processing: Implications of the specific actions of clozapine compared with haloperidol.

J. Ishigooka, M. Yamada, K. Inada, 2016, European journal of pharmacology.

Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics

Y. Hirano, T. Onitsuka, K. Ohi, 2023, Journal of clinical psychopharmacology.

Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project

T. Onitsuka, T. Kishimoto, K. Ohi, 2023, BMC Psychiatry.

Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry

T. Onitsuka, T. Kishimoto, K. Ohi, 2022, Neuropsychopharmacology reports.

Hypotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.

T. Onitsuka, K. Miura, K. Ohi, 2021, Sleep medicine.

Posterior Reversible Encephalopathy Syndrome Due to Acute Water Intoxication in a Patient with Schizophrenia

R. Akaho, K. Nishimura, Atsuko Inoue, 2020, International Medical Case Reports Journal.

Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study

T. Kishimoto, K. Ohi, N. Yasui-Furukori, 2023, Psychiatry and clinical neurosciences.

Diazepam suppresses the stress‐induced dopaminergic release in the amygdala of methamphetamine‐sensitized rat

K. Nishimura, J. Ishigooka, M. Yamada, 2018, European journal of pharmacology.

Effects of chronic haloperidol treatment on the expression of fear memory and fear memory extinction in the cued fear‐conditioned rats

K. Nishimura, J. Ishigooka, H. Oshibuchi, 2024, Neuropsychopharmacology reports.

Effect of intermittent subchronic MK‐801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex

K. Nishimura, J. Ishigooka, T. Fuwa, 2024, Neuropsychopharmacology reports.